Multivalent Group B streptococcus vaccine
Sponsors
Pfizer
Conditions
Group B Streptococcal InfectionsGroup B Streptococcus InfectionsHealthy
Phase 2
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
CompletedNCT03170609
Start: 2017-06-05End: 2018-06-25Updated: 2019-07-02
Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants
CompletedNCT03765073
Start: 2019-01-14End: 2024-03-04Updated: 2025-08-05
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
CompletedNCT04766086
Start: 2022-08-12End: 2023-04-27Updated: 2024-05-24